AURORA CANNABIS: Improving cost structure but remains loss making | SELL | CAD20 vs. CAD13.2
AURORA CANNABIS - SELL | CAD20 vs. CAD13.2 (-11%)Improving cost structure but remains loss making
Q3 revenues increased 15% sequentially
Steep progress in cutting costs
COVID-19 Comments.
No further capital raises needed(?)
Estimate revisions
Entering the US with the Reliva acquisition
Recap of the business transformation plan
Aurora Cannabis is engaged in the acquisition, exploration and development of resource properties, primarily in Canada.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.